A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.
Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabete...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2012-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3446875?pdf=render |
id |
doaj-6fa0a48c7b514183a391979a8da17897 |
---|---|
record_format |
Article |
spelling |
doaj-6fa0a48c7b514183a391979a8da178972020-11-25T01:53:29ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4526910.1371/journal.pone.0045269A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin.Margaret P RaymanGabrielle Blundell-PoundRoberto Pastor-BarriusoEliseo GuallarHolger SteinbrennerSaverio StrangesEvidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen.In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available.Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96).These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status.http://europepmc.org/articles/PMC3446875?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Margaret P Rayman Gabrielle Blundell-Pound Roberto Pastor-Barriuso Eliseo Guallar Holger Steinbrenner Saverio Stranges |
spellingShingle |
Margaret P Rayman Gabrielle Blundell-Pound Roberto Pastor-Barriuso Eliseo Guallar Holger Steinbrenner Saverio Stranges A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. PLoS ONE |
author_facet |
Margaret P Rayman Gabrielle Blundell-Pound Roberto Pastor-Barriuso Eliseo Guallar Holger Steinbrenner Saverio Stranges |
author_sort |
Margaret P Rayman |
title |
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
title_short |
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
title_full |
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
title_fullStr |
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
title_full_unstemmed |
A randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
title_sort |
randomized trial of selenium supplementation and risk of type-2 diabetes, as assessed by plasma adiponectin. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2012-01-01 |
description |
Evidence that selenium affects the risk of type-2 diabetes is conflicting, with observational studies and a few randomized trials showing both lower and higher risk linked to the level of selenium intake and status. We investigated the effect of selenium supplementation on the risk of type-2 diabetes in a population of relatively low selenium status as part of the UK PRECISE (PREvention of Cancer by Intervention with SElenium) pilot study. Plasma adiponectin concentration, a recognised independent predictor of type-2 diabetes risk and known to be correlated with circulating selenoprotein P, was the biomarker chosen.In a randomized, double-blind, placebo-controlled trial, five hundred and one elderly volunteers were randomly assigned to a six-month intervention with 100, 200 or 300 µg selenium/d as high-selenium or placebo yeast. Adiponectin concentration was measured by ELISA at baseline and after six months of treatment in 473 participants with one or both plasma samples available.Mean (SD) plasma selenium concentration was 88.5 ng/g (19.1) at baseline and increased significantly in the selenium-treatment groups. In baseline cross-sectional analyses, the fully adjusted geometric mean of plasma adiponectin was 14% lower (95% CI, 0-27%) in the highest than in the lowest quartile of plasma selenium (P for linear trend = 0.04). In analyses across randomized groups, however, selenium supplementation had no effect on adiponectin levels after six months of treatment (P = 0.96).These findings are reassuring as they did not show a diabetogenic effect of a six-month supplementation with selenium in this sample of elderly individuals of relatively low selenium status. |
url |
http://europepmc.org/articles/PMC3446875?pdf=render |
work_keys_str_mv |
AT margaretprayman arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT gabrielleblundellpound arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT robertopastorbarriuso arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT eliseoguallar arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT holgersteinbrenner arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT saveriostranges arandomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT margaretprayman randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT gabrielleblundellpound randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT robertopastorbarriuso randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT eliseoguallar randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT holgersteinbrenner randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin AT saveriostranges randomizedtrialofseleniumsupplementationandriskoftype2diabetesasassessedbyplasmaadiponectin |
_version_ |
1724990725897060352 |